Nektar Therapeutics Income Statement (2010-2026) | NKTR

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	28.33M	24.92M	25.01M	24.82M	21.59M	23.62M	22.02M	21.59M	20.50M	24.14M	23.89M	21.64M	23.49M	24.12M	29.18M	10.46M	11.18M	11.79M	21.81M	10.86M
Cost of Revenue (Quarter)	7.67M	5.31M	6.16M	5.32M	5.12M	4.97M	6.23M	7.06M	6.99M	12.43M	10.56M	11.21M	11.22M	11.01M	19.34M	17.26M		10.30M		7.70M
Gross Profit (Quarter)	20.66M	19.61M	18.85M	19.51M	16.47M	18.65M	15.79M	14.53M	13.51M	11.71M	13.32M	10.43M	12.27M	13.11M	9.84M	-6.80M	11.18M	1.49M	21.81M	3.16M
Operating items
Research & Development (Quarter)	101.31M	103.74M	99.61M	107.25M	42.74M	33.59M	34.74M	30.47M	29.68M	24.07M	29.94M	27.41M	29.72M	35.03M	28.75M	30.48M	29.89M	27.25M	29.71M	35.68M
Selling, General & Administrative (Quarter)	29.55M	29.47M	32.14M	27.34M	20.52M	22.53M	21.94M	21.08M	17.87M	21.15M	17.32M	20.15M	20.51M	18.96M	17.14M	24.35M	17.07M	16.07M	11.19M	13.44M
Restructuring Costs (Quarter)				1.48M	106.05M	16.83M	11.58M	1.60M	1.36M	0.54M	-41.21M	0.97M	13.29M	0.05M	1.36M	0.17M	0.45M	0.14M	8.57M	0.80M
Other Operating Expenses (Quarter)	7.67M	5.31M	6.16M	5.32M	5.12M	4.97M	6.23M	103.16M	22.19M	23.26M	-153.13M	8.53M	-44.69M	-48.66M	-198.63M	-50.53M	-43.29M
Operating Expenses (Quarter)	138.53M	138.52M	137.92M	141.38M	174.42M	77.93M	74.49M	156.30M	71.10M	69.01M	-147.07M	57.07M	18.84M	5.38M	-151.39M	4.46M	4.11M	43.46M	49.47M	49.91M
Operating Income (Quarter)	-110.20M	-113.60M	-112.91M	-116.56M	-152.84M	-54.30M	-52.47M	-134.71M	-50.60M	-44.86M	-33.51M	-35.43M	-49.77M	-34.34M	14.35M	-44.53M	-36.23M	-31.67M	-27.66M	-39.05M
EBIT (Quarter)	-110.20M	-113.60M	-112.91M	-116.56M	-152.84M	-54.30M	-52.47M	-134.71M	-50.60M	-44.86M	-33.51M	-35.43M	-49.77M	-34.34M	14.35M	-44.53M	-36.23M	-31.67M	-27.66M	-39.05M
Non-operating items
Interest & Investment Income (Quarter)								4.33M	4.85M	5.21M	4.62M	4.22M	3.90M	3.44M	2.94M	2.87M	1.97M	2.82M	2.78M	4.24M
Other Non Operating Income (Quarter)	-2.71M	0.13M	12.37M	33.43M			-3.66M	-0.30M	-1.03M	-0.34M	1.09M	-0.10M	-0.04M	-0.12M	-7.49M	0.27M	0.26M	-0.12M	-0.41M	-0.34M
Non Operating Income (Quarter)	-14.96M	-16.00M	-32.74M	26.29M	-6.13M	-4.90M	-4.08M	-2.37M	-0.57M	-1.03M	-8.60M	-1.41M	-2.54M	-2.70M	-7.35M	-1.83M	-3.17M	-3.35M	-7.04M	-4.04M
Net income details
EBT (Quarter)	-125.16M	-129.59M	378.79M	-90.27M	-158.97M	-59.20M	-56.54M	-137.08M	-51.17M	-45.90M	-42.11M	-36.84M	-52.32M	-37.05M	7.00M	-46.37M	-39.40M	-35.02M	-34.70M	-43.09M
Tax Provisions (Quarter)	0.36M	0.11M	-0.00M	0.13M	0.10M	-0.15M	-76.72M	-0.06M	-0.05M	-0.06M	-0.03M	-0.04M	0.05M	0.01M	-25.05M	0.05M	-0.19M	-0.03M	-34.32M	0.06M
Profit After Tax (Quarter)	-125.80M	-129.71M	-145.65M	-92.77M	-160.73M	-59.05M	-59.69M	-135.79M	-51.89M	-45.84M	-42.08M	-37.28M	-52.45M	-37.06M	7.26M	-50.88M	-41.65M	-35.52M	-36.08M	-44.90M
Income from Continuing Operations (Quarter)	-125.52M	-129.71M	378.80M	-90.39M	-159.07M	-59.05M	20.17M	-137.02M	-51.12M	-45.84M	-42.08M	-36.80M	-52.36M	-37.06M	32.05M	-46.42M	-39.21M	-34.99M	-0.39M	-43.15M
Consolidated Net Income (Quarter)	-125.52M	-129.71M	378.80M	-90.39M	-159.07M	-59.05M	20.17M	-137.02M	-51.12M	-45.84M	-42.08M	-36.80M	-52.36M	-37.06M	32.05M	-46.42M	-39.21M	-34.99M	-0.39M	-43.15M
Income towards Parent Company (Quarter)	-125.52M	-129.71M	378.80M	-90.39M	-159.07M	-59.05M	20.17M	-137.02M	-51.12M	-45.84M	-42.08M	-36.80M	-52.36M	-37.06M	32.05M	-46.42M	-39.21M	-34.99M	-0.39M	-43.15M
Net Income towards Common Stockholders (Quarter)	-125.52M	-129.71M	378.80M	-90.39M	-159.07M	-59.05M	20.17M	-137.02M	-51.12M	-45.84M	-42.08M	-36.80M	-52.36M	-37.06M	32.05M	-46.42M	-39.21M	-34.99M	-0.39M	-43.15M
Additional items
EPS (Basic) (Quarter)	-10.30	-10.57	31.00	-7.30	-12.77	-4.72	1.62	-10.88	-4.04	-3.61	-3.32	-2.83	-3.76	-2.66	2.34	-3.30	-2.78	-1.85	-0.02	-1.74
EPS (Diluted) (Quarter)	-10.30	-10.57	31.00	-7.30	-12.77	-4.72	1.62	-10.88	-4.04	-3.61	-3.32	-2.83	-3.76	-2.66	2.34	-3.30	-2.78	-1.85	-0.02	-1.74
Shares Outstanding (Quarter)	12.18M	12.27M	12.22M	12.39M	12.45M	12.51M	12.48M	12.59M	12.64M	12.69M	12.67M	12.98M	13.92M	13.95M	13.71M	14.06M	14.09M	18.95M	16.87M	24.74M
Shares Outstanding (Diluted) (Quarter)	12.18M	12.27M	12.22M	12.39M	12.45M	12.51M	12.48M	12.59M	12.64M	12.69M	12.67M	12.98M	13.92M	13.95M	13.71M	14.06M	14.09M	18.95M	16.87M	24.74M
Shares Outstanding (Entity) (Quarter)	12.25M	12.30M	12.37M	12.42M	12.49M	12.53M	12.57M	12.62M	12.68M	12.72M	12.76M	12.79M	12.82M	12.85M	12.94M	12.96M	13.01M	19.65M	16.87M	29.47M
EBITDA (Quarter)	-110.20M	-113.60M	-112.91M	-116.56M	-152.84M	-54.30M	-52.47M	-134.71M	-50.60M	-44.86M	-33.51M	-35.43M	-49.77M	-34.34M	14.35M	-44.53M	-36.23M	-31.67M	-27.66M	-39.05M
Interest Expenses (Quarter)	13.09M	12.80M	-22.39M	7.53M	7.23M	6.95M	7.20M	6.41M	6.15M	5.91M	6.87M	5.53M	6.41M	6.02M	10.15M	4.97M	5.39M	6.05M	9.77M	7.94M
Tax Rate (Quarter)	-0.29%	-0.09%	0.00%	-0.14%	-0.06%	0.26%	135.68%	0.05%	0.09%	0.13%	0.07%	0.10%	-0.09%	-0.02%	-357.78%	-0.11%	0.48%	0.09%	98.89%	-0.15%

Research Tools

Developers

Nektar Therapeutics Income Statement (2010-2026) | NKTR

Research Tools

Developers

Nektar Therapeutics Income Statement (2010-2026) | NKTR

Create an account

Sign In

Reset Password